YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Entrada Therapeutics press release [https://seekingalpha.com/pr/20607419-entrada-therapeutics-reports-second-quarter-2026-financial-results] (TRDA [https://seekingalpha.com/symbol/TRDA]): Q2 net loss was $42.8M vs $43.1M for Q2, 2025. *…
Entrada Therapeutics, Inc. -- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Coh…
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Comp…
LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or “the Company”) (…
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA). The investigation focuses on Entrada’s executive officers and whether i…
Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys. Continue Reading
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Entrada Therapeutics, Inc. (TRDA) shares rallied 8.9% in the last trading session to close at $15.79. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to t…
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.…
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index and the State Str PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
5AM Venture Management disclosed a full exit from Dianthus Therapeutics(NASDAQ:DNTH) on February 17, 2026, selling 365,053 shares worth $14.36 million in the fourth quarter. What happened According to a Securities and Exchange Commission (…
Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position…
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines(NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values. What happened According to a Securities an…
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive employees under the Compa…
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non-re…
Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items. This…
Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago. These figures are adjusted for non-recurring items. This…
Techne (TECH) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items. This q…
This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Tuesday. This is TheStreet’s Stock Market Today for Jan. 13, 2026. You can…
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and…
ismagilov / iStock via Getty Images As the year winds down, many investors are positioning themselves for 2026 and beyond. Some insiders made big insider purchases while others might be out for the holidays. The year’s largest initial publ…
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wedn…
Entrada Therapeutics, Inc. BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan He…
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s comm…
Key Points San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million. 5AM still ho…
Key Points San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million. 5AM still ho…
Key Points Exited entire position: down 189,593 shares, a net position change of $5.02 million No remaining shares held; post-trade stake is zero The position previously accounted for approximately 1.9% of the fund’s AUM in the prior quart…
Key Points Sold 282,313 shares for an estimated $13.33 million net change Post-sale, the fund holds zero shares valued at $0 The position was previously 5.12% of the fund’s assets as of last quarter These 10 stocks could mint the next wave…
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.35 per share a year ago. These figures are adjusted for non-recurring…
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.63 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.8 per share a year ago. These figures are adjusted for non-recurring i…
Janux Therapeutics, Inc. (JANX) shares rallied 8.8% in the last trading session to close at $29.76. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne…
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s com…
Entrada Therapeutics Inc (NASDAQ:TRDA [https://www.chartmill.com/stock/quote/TRDA]) reported its second-quarter 2025 financial results, missing analyst estimates on both revenue and earnings per share (EPS). The company posted revenue of $…
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activat…
Director Kush Parmar reported selling shares of Entrada Therapeutics , Inc. (NASDAQ:TRDA) on July 9, 2025. The sales involved 27,000 shares of common stock, netting approximately $202,554. The transaction comes as the stock trades near its…